Last reviewed · How we verify

Opioid-free Anesthesia-Analgesia Strategy

University of Crete · FDA-approved active Small molecule

A multimodal anesthesia-analgesia strategy that avoids opioid medications by combining regional anesthesia, local anesthetics, and non-opioid analgesics.

A multimodal anesthesia-analgesia strategy that avoids opioid medications by combining regional anesthesia, local anesthetics, and non-opioid analgesics to provide perioperative pain control. Used for Perioperative anesthesia and analgesia in surgical patients.

At a glance

Generic nameOpioid-free Anesthesia-Analgesia Strategy
Also known asOpioid-Free Anesthesia, OFA-A
SponsorUniversity of Crete
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

This approach uses a combination of techniques including neuraxial blockade, peripheral nerve blocks, local infiltration anesthesia, and non-opioid systemic medications (such as NSAIDs, acetaminophen, ketamine, and dexmedetomidine) to achieve anesthesia and analgesia without relying on opioid drugs. The strategy aims to reduce opioid-related adverse effects including respiratory depression, addiction potential, and postoperative nausea while maintaining effective pain control and anesthetic depth.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: